


I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on May 30, 2007.


Frank C. Eisenschenk, Ph.D., Patent Attorney

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
Examining Group 1646
Patent Application
Docket No. INN-133
Serial No. 10/563,045

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1646
Applicants : Alessandro Moretta, Mariella Della Chiesa
Serial No. : 10/563,045
Filed : December 30, 2005
Conf. No. : 6062
For : PAN-KIR2DL NK-Receptor Antibodies and Their Use in Diagnostik and Therapy

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed. However, Applicants have not submitted a copy of the U.S. patent cited on attached Form PTO/SB/08 pursuant to 37 C.F.R. 1.98(a)(2)(ii).


It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Published International Application No. WO 00/26671, cited as F1 on the attached form PTO/SB/08, is written in a foreign language; however, an English language Abstract is provided

therewith. Applicants respectfully request that this reference be made of record and considered in the examination of the subject application.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/sl

Attachments: Form PTO/SB/08; copies of cited references.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/563,045
				Filing Date	December 30, 2005
				First Named Inventor	Alessandro Moretta
				Art Unit	1646
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	INN-133

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US-5,808,028	09-15-1998	LONG <i>et al.</i>	All
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1	WO 00/26671 A1	05-11-2000	CONNEX GmbH	All	
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/563,045	
			Filing Date	December 30, 2005	
			First Named Inventor	Alessandro Moretta	
			Group Art Unit	1646	
			Examiner Name		
Sheet	2	of	2	Attorney Docket Number	INN-133

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	COLONNA, M. <i>et al.</i> "Cloning Of The Immunoglobulin-Superfamily Members Associated With HLA-C And HLA-B Recognition By Human Natural Killer Cells", <i>Science</i> , April 21, 1995, pp. 405-408, Vol. 268.	
	R2	DATABASE GENESEQ ONLINE Accession No. AAE17798, "E. coli Monoclonal Antibody Heavy Chain Variable Region CDR#2", May 7, 2002, XP-002309301.	
	R3	DATABASE GENESEQ ONLINE Accession No. AAW01153, "MAb 10.1 Light Chain CDR (MAb Binds Type II Phospholipase A2)", February 10, 1997, XP-002309300.	
	R4	DATABASE GENESEQ ONLINE Accession No. ABG74248, "Mouse Antibody 3E11 Light Chain Variable Region", April 22, 2003, XP-002309299.	
	R5	KARRE, K. <i>et al.</i> "Selective Rejection of H-2-Deficient Lymphoma Variants Suggests Alternative Immune Defence Strategy", <i>Nature</i> , February 20, 1986, pp. 675-678, Vol. 319.	
	R6	LANIER, L. "NK Cell Receptors", <i>Annu. Rev. Immunol.</i> , 1998, pp. 359-393, Vol. 16.	
	R7	MORETTA, A. <i>et al.</i> "Function And Specificity Of Human Natural Killer Cell Receptors", <i>Eur. J. Immunogenetics</i> , 1997, pp. 455-468, Vol. 24.	
	R8	OHLEN, C. <i>et al.</i> "Studies Of Sublines Selected For Loss Of HLA Expression From An Ebv-Transformed Lymphoblastoid Cell Line. Changes In Sensitivity To Cytotoxic T Cells Activated By Allostimulation And Natural Killer Cells Activated By IFN Or IL-2", <i>J Immunol.</i> , May 1, 1989, pp. 3336-3341, Vol. 142, No. 9.	
	R9	POGGI, A. <i>et al.</i> "P40, A Novel Surface Molecule Involved In The Regulation Of The Non-Major Histocompatibility Complex-Restricted Cytolytic Activity In Humans", <i>European Journal Of Immunology</i> , 1995, pp. 369-376, Vol. 25.	
	R10	SPAGGIARI, G. M. <i>et al.</i> "Soluble HLA class I Molecules Induce Natural Killer Cell Apoptosis Through The Engagement Of CD8: Evidence For A Negative Regulation Exerted By Members Of The Inhibitory Receptor Superfamily", <i>Blood</i> , March 1, 2002, pp. 1706-1714, Vol. 99, No. 5.	
	R11	VALIANTE, N. <i>et al.</i> "Killer Cell Receptors: Keeping Pace With MHC Class I Evolution", <i>Immunol. Rev.</i> , 1997, pp. 155-164, Vol. 155.	
	R12	WATZL, C. <i>et al.</i> "Homogenous Expression Of Killer Cell Immunoglobulin-Like Receptors (KIR) On Polyclonal Natural Killer Cells Detected By A Monoclonal Antibody To KIR2D", <i>Tissue Antigens</i> , 2000, pp. 240-247, Vol. 56.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.